
There’s never been a more exciting time for all of us to take on cancer, together.
✓Clinical Computational Oncology @DanaFarber @harvardmed @broadinstitute | Chief AI Officer & PopSci | Prev: @Stanford @UCLA @UCSF | Disc: bit.ly/2kF9C7B

There’s never been a more exciting time for all of us to take on cancer, together.

We are pleased share information about our new Harvard-based Radiation Oncology Residency Program @DanaFarber @BIDMChealth @BostonChildrens . Please let your interested med students know! dana-farber.org/for-physicia…

I salute you, Flock Keeper, the hero we need in these uncertain times ... massdailynews.com/2026/11/05…

1/11 Excited to share GENESIS, a generative model for predicting single-cell perturbation responses in unmeasured experimental conditions. We show near-experimental-reproducibility performance, strong sample efficiency, and recovery of cancer signaling programs. 🧵

Early detection matters! 💗 I'm sharing my personal breast cancer story and how a routine screening mammogram led to an early diagnosis that made all the difference. Watch my story and learn why early detection is so important. Get screened—it could save your life! 🎀 Breast cancer doctor faces her own diagnosis goodmorningamerica.com/video… via @GMA

We are now accepting applications for the T32 postdoctoral fellowship training program: Training in Oncology Population Sciences (TOPS) Applications are due 12/16 and accepted fellows will begin their training in September 2027. TOPSPostdoc.org

In case anyone is running agents and wondering if you can leave them running on a holiday, know that Chabad is on the case! chabad.org/library/article_c…

New work from Pasi A. Jänne, us, and 23andme; led by Jackie LoPiccolo and Steven Micheletti. Characterizing a highly penetrant germline founder mutation for lung cancer.

In our latest, we continued multi-omic exploration of GI neuroendocrine tumors, finding potential organ-specific molecular programs and microenvironmental niches - congrats Julie Karam @SamHoffmanMed et al! @DanaFarber @broadinstitute @jclinicalinvest jci.org/articles/view/204119

🚨We are hiring! 🚨 The Department of Biostatistics @HarvardChan and the Department of Data Science @DanaFarber are recruiting a tenure-track Assistant/Associate Professor in statistics or machine learning with interests in single-cell or spatial genomics. Link below 👇

In our latest, we studied how certain immune cells surround bladder tumors and contribute to chemotherapy resistance, pointing to a surprising potential therapeutic target ... Congrats @CarvalhoFilipeL @mouwlab et al! @CellPressNews @cellpressblue cell.com/cell-press-blue/ful…

Here's our latest in @cellpressblue. In collaboration with @VanAllenLab and @mouwlab, we asked a simple question: Why do some muscle-invasive bladder cancers survive neoadjuvant chemotherapy? 🧵cell.com/cell-press-blue/ful… Congrats to @JihyunkaLee et al!

Very exciting new method for inferring latent disease trajectories, led by the tireless Dr. Urbut with Natarajan and Parmigiani labs. If you're considering a postdoc in this area talk to Sarah!

One of my first consults as a cardiology fellow: a 34-year-old, textbook MI. A day earlier, no risk model would have flagged him for prevention. That paradox has driven my work ever since — our models miss how disease actually evolves, dynamically, on top of a genetic background. @Nature nature.com/articles/s41586-0…

Please repost! We are seeking #PostDocs to join our lab in @YaleGenetics @YaleCancer @CancerYale to study #genetic and #host drivers of #PancreaticCancer and #LungCancer. Check out our newly updated website for more lab details! medicine.yale.edu/lab/muzumd…

📣Delighted to share two new studies from our team using germline genome sequencing 🧬 to understand #cancer #predisposition! Interested? 🧵👇 for details 1/15